← Leaderboards
Corey R. Hopkins
University Of Nebraska Medical Center
$7,733,878
Attributed
$11,203,702
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,203,702 · 8
By mechanism
R01$9,253,060 · 5
R33$1,177,500 · 1
R21$773,142 · 2
Top collaborators
- Punita Dhawan6 shared
- C David Weaver5 shared
- Jerod S Denton3 shared
- Kevin D Wickman3 shared
- Xinmin Simon Xie3 shared
- Peter M Piermarini2 shared
Most similar at University Of Nebraska Medical Center
Same institution · by research overlap
- Jing Wang$7,390,496
- Punita Dhawan$3,662,344
- Simon Sherman$5,087,859
- Whitney S Goldner$75,250
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroPharmaceutical ChemistryDrug KineticsPropertyIn VivoMouse ModelReceptorAnalogBindingToxicologyLeadPlayIn Vivo EvaluationChemical SynthesisCellular AssayBrainSolubilityScaffoldPenetrationBinding ProteinsDesignFamilyDoseCharacteristics
Grant awards (28)
Discovery and characterization of selective GIRK1/2 activators and their evaluation in preclinical models of pain$546,237
R01 · FY2025 · NS · contact PI
Discovery and characterization of selective D4R antagonists and their evaluation in preclinical models of PD-LIDs$416,487
R01 · FY2025 · NS · contact PI
Discovery and characterization of selective D4R antagonists and their evaluation in preclinical models of PD-LIDs$519,278
R01 · FY2024 · NS · contact PI
Impact of CLDN1 inhibition on chemoresistance and metastasis of colon cancer$213,771
R01 · FY2024 · CA
Impact of CLDN1 inhibition on chemoresistance and metastasis of colon cancer$1
R01 · FY2024 · CA
Discovery and characterization of selective D4R antagonists and their evaluation in preclinical models of PD-LIDs$559,991
R01 · FY2023 · NS · contact PI
Impact of CLDN1 inhibition on chemoresistance and metastasis of colon cancer$548,542
R01 · FY2023 · CA
Discovery and characterization of selective GIRK1/2 activators and their evaluation in preclinical models of pain$528,713
R01 · FY2023 · NS · contact PI
Impact of CLDN1 inhibition on chemoresistance and metastasis of colon cancer$238,397
R01 · FY2023 · CA
Discovery and characterization of selective GIRK1/2 activators and their evaluation in preclinical models of pain$548,842
R01 · FY2022 · NS · contact PI
Impact of CLDN1 inhibition on chemoresistance and metastasis of colon cancer$461,779
R01 · FY2022 · CA
Discovery and characterization of selective D4R antagonists and their evaluation in preclinical models of PD-LIDs$395,322
R01 · FY2022 · NS · contact PI
Impact of CLDN1 inhibition on chemoresistance and metastasis of colon cancer$571,142
R01 · FY2021 · CA
Optimization of MrgX1 allosteric agonists as potential therapies for chronic pain$392,500
R33 · FY2021 · DA · contact PI
Discovery and characterization of selective D4R antagonists and their evaluation in preclinical models of PD-LIDs$380,470
R01 · FY2021 · NS · contact PI
Optimization of MrgX1 allosteric agonists as potential therapies for chronic pain$392,500
R33 · FY2020 · DA · contact PI
Optimization of MrgX1 allosteric agonists as potential therapies for chronic pain$392,500
R33 · FY2019 · DA · contact PI
Optimization of novel inhibitors of TRPC5 as anti-proteinuric therapeutics$317,070
R01 · FY2018 · DK · contact PI
Development of small molecule mosquitocides for controlling the primary vector of Zika virus, Aedes aegypti$192,317
R21 · FY2018 · AI
Development of an In Vivo, Brain-penetrant GIRK1/2 Potassium Channel Activator$512,143
R01 · FY2017 · MH
Optimization of MrgX1 allosteric agonists as potential therapies for chronic pain$325,005
R21 · FY2017 · DA · contact PI
Optimization of novel inhibitors of TRPC5 as anti-proteinuric therapeutics$317,070
R01 · FY2017 · DK · contact PI
Development of small molecule mosquitocides for controlling the primary vector of Zika virus, Aedes aegypti$255,820
R21 · FY2017 · AI
Development of an In Vivo, Brain-penetrant GIRK1/2 Potassium Channel Activator$512,143
R01 · FY2016 · MH
Optimization of novel inhibitors of TRPC5 as anti-proteinuric therapeutics$359,080
R01 · FY2016 · DK · contact PI
Development of an In Vivo, Brain-penetrant GIRK1/2 Potassium Channel Activator$583,297
R01 · FY2015 · MH
Optimization of novel inhibitors of TRPC5 as anti-proteinuric therapeutics$355,230
R01 · FY2015 · DK · contact PI
Optimization of novel inhibitors of TRPC5 as anti-proteinuric therapeutics$368,055
R01 · FY2014 · DK · contact PI